<DOC>
	<DOCNO>NCT00181558</DOCNO>
	<brief_summary>The main purpose study look effect ( good bad ) Atrasentan give alone Atrasentan give Zometa level bone formation bone destruction men prostate cancer spread bone .</brief_summary>
	<brief_title>Atrasentan Zometa Men With Prostate Cancer Metastatic Bone</brief_title>
	<detailed_description>- Patients randomize either receive Atrasentan alone Atrasentan plus Zometa . - Patients receive Atrasentan alone receive drug pill form daily 12 week . Patients physical exam , blood work , urine sample perform every week first four week medication administration . After two initial visit , return clinic every 4 week test repeat . A bone scan abdominal-pelvic CT Scan do every 12 week . - After patient take Atrasentan 12 week , disease progress , begin combination treatment Atrasentan Zometa . - Patients receive Atrasentan plus Zometa , receive Zometa intravenously immediately start Atrasentan orally daily long remain study . Patients return clinic twice first 4 week ( every week ) physical exam , blood work urine test perform . After two initial visit , return clinic every 4 week test repeat receive another treatment zometa . A bone scan abdominal-pelvic CT Scan do every 12 week . - Patients participation study last long disease progress experience serious side effect .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate History bilateral orchiectomy current treatment GnRH agonist antagonist Radiographically document bone metastasis Disease progression accord criterion PSA Working Group Prior treatment Atrasentan Zometa within one year Serum creatinine &gt; 2.0mg/dL Documented cardiovascular disability status New York Heart Association Class 2 Treatment chemotherapy , radiation , steroid , estrogen , PCSPES within 6 week Treatment bisphosphonates radiopharmaceutical within 12 week History Paget 's disease , hyperthyroidism , hyperparathyroidism , Cushing 's syndrome , hyperprolactinemia disorder associate metabolic bone disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>Atrasentan</keyword>
	<keyword>Zometa</keyword>
	<keyword>Androgen Independent Prostate Cancer</keyword>
</DOC>